Genetic Medicines for Health and Longevity

Powerful therapeutics, not lifestyle longevity.

Oisín Biotechnologies is developing a new class of genetic medicines that target the biology of aging. We don't make pills or supplements, we build powerful, redosable genetic therapies and start with indications regulators already understand, so we can attack the mechanisms of age-related decline on a path that leads to approval.

Our therapies leverage a new, non-viral delivery technology known as Fusogenix™ Proteo-Lipid Vehicle (PLV). This technology enables extensive extrahepatic biodistribution for both DNA and RNA payloads and permits safe repeated dosing.

Platform – Delivery is the problem. Delivery is the moat.

Our therapies are built on the Fusogenix Proteo-Lipid Vehicle (PLV), a non-viral delivery technology that fuses directly with target-cell membranes to deliver both DNA and RNA payloads.

Delivery has been the Achilles' heel of genetic medicine. Viral approaches can't be safely redosed, carry limited payloads, and struggle to reach tissues beyond the liver. Fusogenix PLV combines the efficiency of viral delivery with the safety and scalability of non-viral systems:

  • Redosable: designed for repeat administration, unlike one-shot viral therapies

  • Targetable: extensive biodistribution to tissues throughout the body, not just the liver

  • Large payloads: accommodates cargoes that exceed the limits of conventional vectors

  • Safe: local administration stays where it's placed, without systemic exposure

The platform's core mechanism was published in Cell in 2024.

Pipeline

Oisín has a growing pipeline that applies one delivery platform across aesthetic and longevity medicine.

Targeted fat removal. A precision therapy that selectively eliminates unwanted fat while sparing surrounding tissue – body contouring with a hypodermic needle rather than surgery. Applications span rare disease and the large and growing market for non-invasive fat reduction.

Muscle building. Genetic therapies that drive targeted growth and preservation of skeletal muscle. Initially local applications in aesthetic muscle growth establish the foundation for systemic therapies that combat the loss of strength and independence that comes with age, and pair with GLP-1 drugs to preserve lean muscle mass.

Longevity biology. A deeper pipeline targeting the fundamental drivers of aging, including klotho and other longevity-associated factors, extracellular-matrix remodeling, mitochondrial function, cellular reprogramming, and clearance of senescent cells.

Why now

The rise of GLP-1 drugs, from under $90 million in 2005 to more than $70 billion today, created the most valuable pharmaceutical company in the world and proved how much patients will pay out of pocket to look and feel better. At the same time, genetic medicine has matured to the point where regulators, industry, and patients are comfortable with genetic interventions at scale. Together, these shifts make a real business in longevity medicine possible for the first time.